These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 25143301)

  • 1. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
    Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
    Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
    Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
    Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.
    Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N
    Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
    Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular genetic evidence for subtypes of oligoastrocytomas.
    Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
    Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
    Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
    Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
    Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
    Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
    Cryan JB; Haidar S; Ramkissoon LA; Bi WL; Knoff DS; Schultz N; Abedalthagafi M; Brown L; Wen PY; Reardon DA; Dunn IF; Folkerth RD; Santagata S; Lindeman NI; Ligon AH; Beroukhim R; Hornick JL; Alexander BM; Ligon KL; Ramkissoon SH
    Oncotarget; 2014 Sep; 5(18):8083-92. PubMed ID: 25257301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
    Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.
    Mellai M; Annovazzi L; Senetta R; Dell'Aglio C; Mazzucco M; Cassoni P; Schiffer D
    J Neurooncol; 2017 Jan; 131(2):213-222. PubMed ID: 27796734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
    Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
    Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
    Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
    J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
    Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
    Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.